RECRUITINGOBSERVATIONAL
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Bronchiectasis
Novel Sensors and Artificial Intelligence for Detection of Acute Pulmonary Exacerbations in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis
About This Trial
The goal of this observational study is to learn about new sensors that measure changes in the body that happen during a chest infection, such as breathing rate and heart rate. This study will be with adults who have either cystic fibrosis or bronchiectasis who start treatment with intravenous antibiotics (usually for around 2 weeks). The main question it aims to answer is the change in sensor measure (such as heart rate) between the start and end of treatment for a chest infection. No follow up visits are required for this study.
Who May Be Eligible (Plain English)
Who May Qualify:
- ≥ 18 years old
- Diagnosis of CF based on genetic testing and /or sweat chloride levels or CT confirmed diagnosis of non-CF bronchiectasis
- Under the care of Royal Papworth Hospital
- Starting IV antibiotics for treatment of APE as defined by the Hill Criteria ²
Who Should NOT Join This Trial:
- Patients unable to provide written willing to sign a consent form
- Lung transplant recipients or on lung transplant waiting list
- Use of long-term oxygen therapy (LTOT) or non-invasive ventilation to manage respiratory failure
- Patients unwilling to consent to their link anonymised data from home monitoring being used for research
- Considered unsuitable for home monitoring in the opinion of the investigator
- Patients being admitted for elective antibiotic treatment (i.e. not being admitted for acute APE treatment)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* ≥ 18 years old
* Diagnosis of CF based on genetic testing and /or sweat chloride levels or CT confirmed diagnosis of non-CF bronchiectasis
* Under the care of Royal Papworth Hospital
* Starting IV antibiotics for treatment of APE as defined by the Hill Criteria ²
Exclusion Criteria:
* Patients unable to provide written informed consent
* Lung transplant recipients or on lung transplant waiting list
* Use of long-term oxygen therapy (LTOT) or non-invasive ventilation to manage respiratory failure
* Patients unwilling to consent to their link anonymised data from home monitoring being used for research
* Considered unsuitable for home monitoring in the opinion of the investigator
* Patients being admitted for elective antibiotic treatment (i.e. not being admitted for acute APE treatment)
Treatments Being Tested
OTHER
Non-Interventional Study
non-interventional
Locations (1)
Royal Papworth Hospital NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom